secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2023-11-20T23:59:59+00:00
Accession:  0001104659-23-119946
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics terminates Interim CFO; CEO assumes principal financial officer role
--------------------------------------------------------------------------------

- On Nov 17, 2023, Marker terminated Danforth Advisors consulting agreement, effective Jan 16, 2024.
- Eliot M. Lurier ceased as Interim CFO and Principal Financial and Accounting Officer immediately.
- CEO Juan Vera appointed as Principal Financial and Accounting Officer effective Nov 17, 2023.
- No replacement CFO has been announced; CEO will handle financial officer duties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923119946/0001104659-23-119946-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923119946/tm2330976d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-119946

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer